Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma

Connell, Louise C.; Harding, James J.; Shia, Jinru; Abou‐Alfa, Ghassan K.

doi:10.21037/cco.2016.10.02

Cited by 39 publications

(44 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In part, the pathologic diagnosis of mixed HCC‐ICC has improved with greater expertise on the part of pathologists probably due to a better definition of the diagnostic criteria. Although a unified criterion for combined HCC‐CC is still not available, a diagnosis of combined HCC‐CC requires evidence of HCC differentiation, such as trabecular growth pattern, bile production, or bile canaliculi as well as clear evidence of ICC, such as true glandular structures formed by biliary‐type epithelium, mucin production or prominent desmoplastic stoma . A diagnosis of mixed HCC‐ICC is typically characterized by an interface where HCC and ICC components intimately intermingle with each other .…”

Section: Discussionmentioning

confidence: 99%

Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A population‐based analysis

Spolverato

Bagante

Tsilimigras

et al. 2018

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background We sought to define the management of mixed hepatocellular carcinoma‐intrahepatic cholangiocarcinoma (HCC‐ICC) as well as characterize short‐ and long‐term outcomes of patients with mixed HCC‐ICC. Methods Patients diagnosed with HCC‐ICC, HCC, or ICC between 2004 and 2015 were identified from the National Cancer Data Base using the International Classification of Diseases for Oncology codes. Short‐ and long‐term outcomes were assessed using univariate and multivariate analyses. Results Among 174 454 patients, 86.8% had HCC, 12.1% ICC, and 1.1% HCC‐ICC. The incidence of lymphadenectomy was 55.6% among ICC patients vs 15.1% and 34.2% for HCC and HCC‐ICC patients, respectively (P < 0.001). A 90‐day mortality was comparable among patients with HCC (9.1%), ICC (8.8%), and HCC‐ICC (10.5%) (all P > 0.2). While 42.0% of ICC patients received adjuvant chemotherapy, adjuvant chemotherapy among HCC and HCC‐ICC patients was 13.1% and 27.4%, respectively (P < 0.001). A 5‐year survival was 43.5% (95% CI, 42.5‐44.5), 33.3% (95% CI, 31.4‐35.3), 34.4% (95% CI, 29.1‐39.8) for HCC, ICC, and HCC‐ICC patients, respectively. Conclusion Patients who underwent resection of mixed HCC‐ICC had a prognosis that was comparable to ICC, yet worse than HCC. Utilization of lymphadenectomy and adjuvant therapy were low. HCC‐ICC remains a rare disease with a guarded prognosis that should be treated in a multidisciplinary setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A population‐based analysis

Spolverato

Bagante

Tsilimigras

et al. 2018

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…In the same solid malignant neoplasm, PLC can be classified according to histological sources. A tumor that contains only cancerous hepatocytes is defined as hepatocellular carcinoma (HCC), only cancerous bile duct cells are defined as intrahepatic cholangiocarcinoma (ICC), and a mixture of HCC and ICC is defined as combined hepatocellular–cholangiocarcinoma (cHCC-ICC) ( 3 , 4 ).…”

Section: Introductionmentioning

confidence: 99%

Ultrasound-Based Radiomics Analysis for Preoperatively Predicting Different Histopathological Subtypes of Primary Liver Cancer

Peng

Lin

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: Preoperative identification of hepatocellular carcinoma (HCC), combined hepatocellular-cholangiocarcinoma (cHCC-ICC), and intrahepatic cholangiocarcinoma (ICC) is essential for treatment decision making. We aimed to use ultrasound-based radiomics analysis to non-invasively distinguish histopathological subtypes of primary liver cancer (PLC) before surgery. Methods: We retrospectively analyzed ultrasound images of 668 PLC patients, comprising 531 HCC patients, 48 cHCC-ICC patients, and 89 ICC patients. The boundary of a tumor was manually determined on the largest imaging slice of the ultrasound medicine image by ITK-SNAP software (version 3.8.0), and then, the highthroughput radiomics features were extracted from the obtained region of interest (ROI) of the tumor. The combination of different dimension-reduction technologies and machine learning approaches was used to identify important features and develop the moderate radiomics model. The comprehensive ability of the radiomics model can be evaluated by the area under the receiver operating characteristic curve (AUC). Results: After digitally processing tumor ultrasound images, 5,234 high-throughput radiomics features were obtained. We used the Spearman + least absolute shrinkage and selection operator (LASSO) regression method for feature selection and logistics regression for modeling to develop the HCC-vs-non-HCC radiomics model (composed of 16 features). The Spearman + statistical test + random forest methods were used for feature selection, and logistics regression was applied for modeling to develop the ICCvs-cHCC-ICC radiomics model (composed of 19 features). The overall performance of the radiomics model in identifying different histopathological types of PLC was moderate, with AUC values of 0.854 (training cohort) and 0.775 (test cohort) in the

show abstract

“…The perihilar area is a very common site of CC, accounting for around half of all cases. [1][2][3][4][5][6][7] How do we explain this disconnect between official data on the proportion of CC which are perihilar and the numbers we see in actual clinical practice? The likely answer is the decades-long systematic error in the recording of perihilar CC by the WHO's International Classification (ICD) system.…”

Section: Global Trends In Mortality From Intrahepatic and Extrahepatimentioning

confidence: 99%

“…These three types of CC are anatomically distinct, have differing epidemiology, pathobiology, clinical presentations and management. 2 The term ''Klatskin" is historic, unclear and should be abandoned in subsequent versions of the ICD and ICD-O classification systems.…”

Section: Global Trends In Mortality From Intrahepatic and Extrahepatimentioning

confidence: 99%

“…To the Editor: We thank Dr. Khan et al for their interest in our work. 1 They are right in pointing out that trends in extrahepatic cholangiocarcinoma (ECC) mirror the long-term declines in gallbladder cancer, 2,3 due to the increase in cholecystectomy. Gallbladder cancer mortality rates in the European Union, in fact, have been declining in women from 2.52/100,000 (world standard) in 1990 to 1.24 in 2015 (À51%).…”

Section: Conflict Of Interestmentioning

confidence: 99%

See 1 more Smart Citation

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

Khan

Genus

Morement³

et al. 2019

Journal of Hepatology

View full text Add to dashboard Cite

No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014;59: 434-442. [4] Cathcart AL, Chan HL, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection. Antimicrob Agents Chemother 2018;62. [5] Ahn SH, Kim DH, Lee AR, Kim BK, Park YK, Park ES, et al. Substitution at rt269 in hepatitis B virus polymerase is a compensatory mutation associated with multi-drug resistance. PLoS ONE 2015;10 e0136728.

show abstract

Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma

Cited by 39 publications

References 0 publications

Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A population‐based analysis

Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A population‐based analysis

Ultrasound-Based Radiomics Analysis for Preoperatively Predicting Different Histopathological Subtypes of Primary Liver Cancer

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

Contact Info

Product

Resources

About